Advanced Hepatocellular Carcinoma
Conditions
Keywords
SBRT, TACE, Lenvatinib
Brief summary
This is a phase 3, multicentri, randomised, open label study. The purpose is to investigate the safety and efficacy of stereotactic body radiation therapy (SBRT) combined with transarterial chemoembolization (TACE) and lenvatinib (LEN) in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus.
Interventions
DRUGLenvatinib
Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients \<60kg, and 12 mg qd for patients ≥ 60kg)
PROCEDURETACE
TACE will be performed one day after oral administration of lenvatinib. Either cTACE or DEB-TACE can be used, depending on the condition of each center.
RADIATIONSBRT
SBRT will be given within 3 weeks after the first TACE with linear accelerator-based photon beams. Gross tumor volume is defined as intrahepatic tumor and vascular invasion including a 1-cm margin into the contiguous HCC. Prescription dose will be 4500-5000 cGy in 5-8 fractions.
Sponsors
Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-75 years old; 2. Patients with primary advanced HCC (in accordance with AASLD2018 guidelines for the diagnosis of HCC), without any previous treatment; 3. There is at least one measurable lesion in the liver according to mRECIST criteria, single tumor ≤ 10.0 cm or multiple tumors and tumor burden ≤50% , with portal vein tumor embolus; 4. ECOG score 0-1; 5. Child-Pugh class A; 6. Expected survival time ≥ 3 months; 7. Blood, liver and kidney function meet the following conditions: Neutrophil count ≥ 1.5 × 10 9 /L; Platelet count ≥ 60 × 10 9 /L; Hemoglobin ≥ 90 g/L; Serum albumin ≥ 30 g/L; Bilirubin ≤ 50 umol/L; AST, ALT ≤ 5 times the upper limit of normal, ALP ≤ 4 times the upper limit of normal; Prolongation of prothrombin time not to exceed the upper limit of normal by 6 seconds; Creatinine ≤ 1.5 times the upper limit of normal.
Exclusion criteria
1. Extrahepatic metastases; 2. Previous history of liver or adjacent tissue radiation; 3. Previous history of hepatic encephalopathy, refractory ascites or gastric esophageal varices; 4. There are contraindications to TACE treatment, such as portosystemic shunt, liver flow ablation, significant atherosclerosis; 5. Hypersensitivity to intravenous contrast agents; 6. Pregnant or lactating women or subjects with family planning within two years; 7. With HIV, syphilis infection; 8. Accompanied by other malignant tumors or suffering from other malignancies within 5 years before enrollment; 9. Allogeneic organ transplant recipients; 10. Severe dysfunction of heart and kidney or other organs; 11. Active severe infection \> grade 2 (NCI-CTC version 5); 12. Suffering from mental and psychological diseases may affect informed consent; 13. Unable to take oral medication; 14. Participated in other drug clinical trials within 12 months before enrollment; 15. Active gastric or duodenal ulcers within 3 months before enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Up to 2 years | OS is defined as the time from first treatment to death, regardless of disease recurrence. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) | Up to 2 years | PFS is defined as the time from the first treatment to progression or death. |
| Objective Response Rate (ORR) | Up to 2 years | ORR is defined as the percentage of patients who have achieved complete response (CR) or partial response (PR), as measured by modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. |
| Disease Control Rate (DCR) | Up to 2 years | DCR is defined as the percentage of patients who have achieved CR, PR or stable disease(SD), as measured by mRECIST criteria. |
| Incidence of Adverse Events (AE) | Up to 2 years | Incidence of AE is defined as the percentage of patients who suffer adverse events from the first treatment to last follow-up, assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. |
| Time to Progression （TTP） | Up to 2 years | TTP is defined as the time from the first treatment to progression. |
Countries
China
Contacts
Primary ContactMing Kuang, Ph.D.
Outcome results
None listed